Effects of Aerobic Training on Exercise Capacity in Patients With Cirrhosis

Aerobic Training in Patients With Cirrhosis

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01799785

Enrollment

Registered

2013-02-27

Start date

2013-02-28

Completion date

2013-07-31

Last updated

2013-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cirrhosis

Brief summary

Cirrhosis is associated with a reduction in muscle mass and exercise capacity. This has an impact or morbidity and mortality. Regular aerobic exercise training is a proven effective therapy to improve exercise capacity in healthy and clinical populations. the effect of this training has not yet been evaluated in cirrhosis. The safety of this intervention also requires further study. Using a randomized controlled design, the investigators aim to conduct a pilot study evaluating the safety and efficacy of eight weeks of aerobic exercise training on aerobic capacity.

Interventions

BEHAVIORALAerobic exercise

Aerobic exercise for 8 weeks (3 times per week, 30-60 minutes each session)

OTHERUsual Care

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Age ≥18 and ≤70 years * Cirrhosis * Child Pugh class A or B * If required, primary or secondary variceal prophylaxis in place

Exclusion criteria

* Post-liver transplantation * Hepatocellular carcinoma * Active non-Hepatocellular carcinoma malignancy * Significant cardiac disease - ejection fraction \<60% or known coronary artery disease * Oxygen saturation at rest \<95% * Known myopathy * Hemoglobin (\<100 g/L) * Chronic renal failure on dialysis * Physical impairment making it impossible to ride an exercise bike or treadmill * Orthopedic abnormality preventing exercise training * HIV infection * Patient unwilling to consent to study

Design outcomes

Primary

Measure	Time frame
Change in peak exercise pulmonary oxygen uptake (peak VO2)	Baseline (day 1) and Study End (8 weeks)

Secondary

Measure	Time frame
Change in muscle mass as measured by thigh ultrasound	Baseline (day 1) and study end (8 weeks)
Change in Quality of Life - Chronic Liver Disease Questionnaire	Baseline (day 1) and Study End (8 weeks)

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 20, 2026